GL1X · GenesisL1 explorer

Research workbench

Crystal structure of ges-5 beta-lactamase in complex with boronic inhibitor cpd 3

Analyse Crystal structure of ges-5 beta-lactamase in complex with boronic inhibitor cpd… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
6Q35
Type
protein
Length
535 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Beta-lactamase
EC
3.5.2.6
UniProt
Q09HD0
Ligands
HD5
Pockets
6 · best druggability 0.71

Structure

x-ray diffraction · 2 distinct chains · 48% helix, 19% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ABeta-lactamase (EC 3.5.2.6)protein26749% helix, 19% strandQ09HD0
BBeta-lactamase (EC 3.5.2.6)protein26848% helix, 19% strandQ09HD0

Ligands and binding sites

  • HD5 · [5-(aminomethyl)-1-benzothiophen-2-yl]boronic acid · ligand · 2 copies · chains A, B
  • EDO · 1,2-ethanediol · additive · 9 copies · chains A, B
  • DMS · Dimethyl sulfoxide · additive · 9 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

6 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
15290.710.8050EDO, DMS
21120.490.8016empty
31010.440.7816EDO
4630.360.7819DMS
5660.350.7719EDO

Interfaces

1 interface between chains.

  • A–B · 948 Ų buried · 23 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 3 covalent, 2 disulfide (covalent ligand, disulfide, additive adduct).

Compared structures

  • 6Q35 · Crystal structure of GES-5 beta-lactamase in complex with boronic inhibitor cpd 3 · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.